Select Medical (SEM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
A special meeting will be held for shareholders to vote on a proposed merger where the company will be acquired by a consortium led by senior executives and WCAS XIV, L.P., taking the company private at $16.50 per share, an 18% premium to the unaffected price and 25% over the 90-day average.
The board formed a Special Committee of independent directors to evaluate the transaction, which, after extensive negotiations and outreach to other potential bidders, unanimously recommended the merger as fair and in the best interests of unaffiliated shareholders.
The merger will be financed through a combination of equity from WCAS, debt financing, and rollover equity from management and certain shareholders, with no financing condition to closing.
If approved, the company will be delisted from the NYSE and become a wholly owned subsidiary of the acquirer; shareholders (other than rollover participants) will receive cash, and appraisal rights are available under Delaware law.
Voting matters and shareholder proposals
Shareholders will vote on: (1) the merger agreement, (2) a non-binding advisory vote on executive compensation related to the merger, and (3) a proposal to adjourn the meeting if more time is needed to solicit votes.
Approval of the merger requires a majority of outstanding shares and a majority excluding shares held by the acquirer and affiliates.
Rollover holders and certain executives have agreed to vote their shares in favor of the merger.
Board of directors and corporate governance
The Special Committee, composed solely of independent and disinterested directors, led the negotiation and evaluation process, retained independent legal and financial advisors, and had full authority over the process.
The board cannot approve the merger without a prior favorable recommendation from the Special Committee.
After the merger, the board of the surviving corporation will be composed of the directors of the merger sub, and current officers will continue in their roles.
Latest events from Select Medical
- Board seeks annual director elections, 25% special meeting threshold, and strong governance.SEM
Proxy Filing4 Mar 2026 - Key votes include board structure changes, executive pay, and special meeting rights.SEM
Proxy Filing4 Mar 2026 - Consortium to acquire all outstanding shares for $16.50 cash per share; company to go private.SEM
Proxy Filing3 Mar 2026 - Board seeks approval for declassification, auditor ratification, and enhanced shareholder rights.SEM
Proxy Filing20 Feb 2026 - Q4 revenue up 6.4% with margin pressure and 2026 guidance; strategic review ongoing.SEM
Q4 202520 Feb 2026 - Q2 revenue up 5.1% to $1.76B, EBITDA rose, and debt reduced after Concentra IPO.SEM
Q2 20242 Feb 2026 - Q3 saw 6% revenue and EBITDA growth, leverage down to 3.38x after Concentra IPO and debt paydown.SEM
Q3 202417 Jan 2026 - Revenue and adjusted EBITDA rose in 2024, with strong segment growth and positive 2025 guidance.SEM
Q4 202423 Dec 2025 - Board recommends key governance changes, pay-for-performance, and strong risk oversight.SEM
Proxy Filing1 Dec 2025